Plain-English translation of NCT06238908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which is delivered as a single intravenous infusion to help your body produce the blood-clotting protein that your hemophilia A prevents you from making naturally. The study will enroll a small group of men (4–6 participants) and gradually increase the dose to understand how safe the medication is and whether it helps reduce bleeding episodes.
Current hemophilia A treatments require frequent injections to replace the missing clotting factor, which can be burdensome and expensive. This trial aims to explore whether a one-time gene therapy infusion could be a more convenient and lasting approach to managing this genetic bleeding disorder.
You likely qualify if…
You likely don't qualify if…
You would receive a single intravenous infusion of the medication in the hospital or clinic. After that, you would be monitored closely for 52 weeks (about one year) with regular visits to check your safety and how well the treatment is working. Following the initial year, you would continue in long-term follow-up for an additional 5 years to track long-term effects and any changes in your bleeding patterns.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China